CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | onium betaine |
|
Accession: | CHEBI:35281
|
browse the term
|
Definition: | Neutral molecules having charge-separated forms with an onium atom which bears no hydrogen atoms and that is not adjacent to the anionic atom. |
Synonyms: | exact_synonym: | betaines |
| related_synonym: | onium betaines |
|
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
decreases expression |
ISO |
Carnitine results in decreased expression of ACACA protein |
CTD |
PMID:25669660 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Acacb |
acetyl-Coenzyme A carboxylase beta |
decreases expression |
ISO |
Carnitine results in decreased expression of ACACB protein |
CTD |
PMID:25669660 |
|
NCBI chr 5:114,284,748...114,388,822
Ensembl chr 5:114,284,596...114,388,822
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
Carnitine results in increased expression of ADIPOQ protein |
CTD |
PMID:30256492 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
increases phosphorylation multiple interactions |
ISO |
Carnitine results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:29186614 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]] |
CTD |
PMID:33290254 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Bax |
BCL2-associated X protein |
decreases expression multiple interactions |
ISO |
Carnitine results in decreased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; Carnitine inhibits the reaction [Atrazine results in increased expression of BAX mRNA]; Carnitine inhibits the reaction [Methotrexate results in increased expression of BAX protein] |
CTD |
PMID:29186614 PMID:36282381 PMID:37312617 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions increases chemical synthesis |
ISO |
Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]] |
CTD |
PMID:21439360 |
|
NCBI chr 2:110,094,401...110,145,158
Ensembl chr 2:110,093,042...110,144,905
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein] |
CTD |
PMID:23213347 PMID:29186614 PMID:36282381 PMID:37312617 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19491382 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO |
Carnitine inhibits the reaction [Atrazine results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of CASP3 protein] Carnitine results in increased expression of CASP3 protein Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein] |
CTD |
PMID:19491382 PMID:23213347 PMID:25669660 PMID:26562095 PMID:32478940 PMID:36282381 PMID:37312617 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein] |
CTD |
PMID:32478940 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA] Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein] |
CTD |
PMID:23213347 PMID:32478940 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA] |
CTD |
PMID:16889571 PMID:19294768 PMID:23213347 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of COL1A1 mRNA] |
CTD |
PMID:26581635 PMID:28973641 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Col2a1 |
collagen, type II, alpha 1 |
multiple interactions |
ISO |
[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine] |
CTD |
PMID:24709313 |
|
NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
multiple interactions |
ISO |
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine] [Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein] |
CTD |
PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions increases expression |
ISO |
Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] Carnitine results in increased expression of CPT2 protein |
CTD |
PMID:21816645 PMID:25669660 |
|
NCBI chr 4:107,761,179...107,780,786
Ensembl chr 4:107,761,178...107,780,807
|
|
G |
Cybb |
cytochrome b-245, beta polypeptide |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein] |
CTD |
PMID:26581635 |
|
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:29710542 |
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein] |
CTD |
PMID:8130774 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Fabp3 |
fatty acid binding protein 3, muscle and heart |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA] |
CTD |
PMID:20470772 |
|
NCBI chr 4:130,202,531...130,209,256
Ensembl chr 4:130,202,388...130,209,256
|
|
G |
Fabp9 |
fatty acid binding protein 9, testis |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein] |
CTD |
PMID:33965443 |
|
NCBI chr 3:10,258,683...10,262,343
Ensembl chr 3:10,258,681...10,262,343
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Carnitine results in decreased expression of FASN protein |
CTD |
PMID:25669660 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fshb |
follicle stimulating hormone beta |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Gdf9 |
growth differentiation factor 9 |
increases expression multiple interactions |
EXP |
Carnitine results in increased expression of GDF9 mRNA Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GDF9 mRNA] |
CTD |
PMID:37863343 |
|
NCBI chr11:53,321,773...53,328,731
Ensembl chr11:53,321,850...53,328,731
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Atrazine results in increased expression of GFAP protein] |
CTD |
PMID:36282381 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression multiple interactions |
EXP |
Carnitine results in increased expression of GJA1 mRNA Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA1 mRNA] |
CTD |
PMID:37863343 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Gja4 |
gap junction protein, alpha 4 |
increases expression multiple interactions |
EXP |
Carnitine results in increased expression of GJA4 mRNA Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA4 mRNA] |
CTD |
PMID:37863343 |
|
NCBI chr 4:127,205,213...127,207,832
Ensembl chr 4:127,205,214...127,207,832
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Atrazine results in increased activity of GPT protein] |
CTD |
PMID:36282381 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA] |
CTD |
PMID:23213347 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein] |
CTD |
PMID:32478940 |
|
NCBI chr 5:30,324,421...30,359,978
Ensembl chr 5:30,323,302...30,360,160
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases expression multiple interactions |
EXP |
Carnitine results in increased expression of HAS2 mRNA Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of HAS2 mRNA] |
CTD |
PMID:37863343 |
|
NCBI chr15:56,529,023...56,557,942
Ensembl chr15:56,529,023...56,557,935
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Methotrexate results in decreased expression of HMOX1 protein] |
CTD |
PMID:37312617 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hrk |
harakiri, BCL2 interacting protein (contains only BH3 domain) |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein] |
CTD |
PMID:16239342 |
|
NCBI chr 5:118,307,829...118,327,543
Ensembl chr 5:118,302,713...118,327,543
|
|
G |
Hspa2 |
heat shock protein 2 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein] |
CTD |
PMID:22359436 |
|
NCBI chr12:76,450,688...76,453,712
Ensembl chr12:76,450,950...76,453,712
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
multiple interactions increases abundance |
EXP |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA] |
CTD |
PMID:26581635 PMID:33965443 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
Carnitine results in increased expression of IL18 protein |
CTD |
PMID:25669660 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA] Carnitine results in increased expression of IL1B protein |
CTD |
PMID:25669660 PMID:26562095 PMID:26581635 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Methotrexate results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA] |
CTD |
PMID:26581635 PMID:33965443 PMID:37312617 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
decreases uptake multiple interactions |
EXP ISO |
INS1 protein results in decreased uptake of Carnitine Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased secretion of INS1 protein] |
CTD |
PMID:28298333 PMID:30256492 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Doxorubicin results in increased activity of LDHA protein] |
CTD |
PMID:37453608 |
|
NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051
|
|
G |
Lepr |
leptin receptor |
affects abundance |
EXP |
LEPR affects the abundance of Carnitine |
CTD |
PMID:20567778 |
|
NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
|
|
G |
Lhb |
luteinizing hormone beta |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
ISO |
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein] |
CTD |
PMID:18597074 PMID:18852009 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
mt-Co1 |
cytochrome c oxidase I, mitochondrial |
multiple interactions |
EXP |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872
|
|
G |
mt-Nd6 |
NADH dehydrogenase 6, mitochondrial |
multiple interactions |
EXP |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:13,552...14,070
Ensembl chr MT:13,552...14,070
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA] |
CTD |
PMID:18299183 |
|
NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein] |
CTD |
PMID:37312617 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
increases expression |
ISO |
Carnitine results in increased expression of NLRP3 protein |
CTD |
PMID:25669660 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA] |
CTD |
PMID:23213347 PMID:33965443 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
increases expression |
ISO |
Carnitine results in increased expression of NOS3 |
CTD |
PMID:20123095 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein] |
CTD |
PMID:33965443 |
|
NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases expression increases activity |
ISO |
[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins] Carnitine results in increased expression of PPARA protein Carnitine results in increased activity of PPARA protein |
CTD |
PMID:19491382 PMID:19735737 PMID:25669660 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
increases expression multiple interactions |
ISO |
Carnitine results in increased expression of PPARG protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein] |
CTD |
PMID:30256492 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Methotrexate results in decreased expression of PPARGC1A protein] |
CTD |
PMID:37312617 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ptgis |
prostaglandin I2 (prostacyclin) synthase |
increases expression increases response to substance multiple interactions |
ISO |
Carnitine results in increased expression of PTGIS mRNA PTGIS protein results in increased susceptibility to Carnitine [Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:19491382 |
|
NCBI chr 2:167,045,114...167,095,069
Ensembl chr 2:167,033,725...167,082,524
|
|
G |
Pycard |
PYD and CARD domain containing |
increases expression |
ISO |
Carnitine results in increased expression of PYCARD protein |
CTD |
PMID:25669660 |
|
NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein] |
CTD |
PMID:33965443 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
decreases expression |
ISO |
Carnitine results in decreased expression of SCD protein |
CTD |
PMID:25669660 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Methotrexate results in decreased expression of SIRT1 protein] |
CTD |
PMID:37312617 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Cyclophosphamide results in increased expression of SIRT3 mRNA] |
CTD |
PMID:37863343 |
|
NCBI chr 7:140,443,576...140,462,222
Ensembl chr 7:140,443,579...140,462,222
|
|
G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
decreases expression |
ISO |
Carnitine results in decreased expression of SLC22A1 protein |
CTD |
PMID:25669660 |
|
NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716
|
|
G |
Slc22a2 |
solute carrier family 22 (organic cation transporter), member 2 |
decreases expression |
ISO |
Carnitine results in decreased expression of SLC22A2 protein |
CTD |
PMID:25669660 |
|
NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375
|
|
G |
Slc22a21 |
solute carrier family 22 (organic cation transporter), member 21 |
multiple interactions increases uptake |
ISO |
[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine] |
CTD |
PMID:19735737 |
|
NCBI chr11:53,840,780...53,871,159
Ensembl chr11:53,840,791...53,871,158
|
|
G |
Slc22a27 |
solute carrier family 22, member 27 |
multiple interactions increases uptake |
EXP |
Acetylcarnitine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Carnitine analog inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Choline inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Cimetidine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Corticosterone inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Cyclic AMP inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; estrone sulfate inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; octanoylcarnitine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Salicylic Acid inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; tetramethylammonium inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine] |
CTD |
PMID:20332632 |
|
NCBI chr19:7,841,753...7,943,899
Ensembl chr19:7,841,753...7,943,392
|
|
G |
Slc22a4 |
solute carrier family 22 (organic cation transporter), member 4 |
increases uptake decreases expression |
ISO |
SLC22A4 protein results in increased uptake of Carnitine Carnitine results in decreased expression of SLC22A4 protein |
CTD |
PMID:21256917 PMID:25669660 PMID:33007874 |
|
NCBI chr11:53,873,941...53,920,866
Ensembl chr11:53,873,949...53,918,916
|
|
G |
Slc22a5 |
solute carrier family 22 (organic cation transporter), member 5 |
multiple interactions affects expression decreases expression increases transport increases uptake increases expression affects uptake affects binding |
ISO EXP |
[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of Doxorubicin]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine affects the expression of SLC22A5 protein Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of and results in increased localization of Doxorubicin] Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine deficiency results in increased expression of SLC22A5 mRNA SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog SLC22A5 protein affects the uptake of Carnitine Carnitine binds to SLC22A5 protein |
CTD |
PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 PMID:18981167 PMID:19041296 PMID:19539806 PMID:19735737 PMID:20303936 PMID:20470772 PMID:21256917 PMID:21641380 PMID:22701146 PMID:25669660 PMID:30465787 PMID:31437515 PMID:33007874 PMID:37453608 More...
|
|
NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486
|
|
G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
increases transport |
EXP |
SLC22A8 protein results in increased transport of Carnitine |
CTD |
PMID:15100168 |
|
NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199
|
|
G |
Slc25a20 |
solute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 20 |
multiple interactions increases transport |
ISO |
Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine] |
CTD |
PMID:18452908 PMID:23402788 |
|
NCBI chr 9:108,539,335...108,561,841
Ensembl chr 9:108,539,287...108,561,840
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions increases expression |
ISO |
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein] Carnitine results in increased expression of SLC2A4 protein |
CTD |
PMID:30256492 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Snai1 |
snail family zinc finger 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA] Carnitine results in decreased expression of SREBF1 protein |
CTD |
PMID:18299183 PMID:25669660 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein] |
CTD |
PMID:33965443 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA] |
CTD |
PMID:26562095 PMID:26581635 PMID:28973641 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions decreases expression |
ISO |
Carnitine deficiency results in increased expression of TNF mRNA [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of TNF protein] Carnitine results in decreased expression of TNF protein |
CTD |
PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 PMID:37312617 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein] |
CTD |
PMID:28973641 |
|
NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637
|
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of CXCL8 protein] |
CTD |
PMID:19041333 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein] |
CTD |
PMID:19041333 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Prnp |
prion protein |
multiple interactions affects folding |
ISO |
Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form] |
CTD |
PMID:20936829 |
|
NCBI chr 2:131,751,848...131,780,356
Ensembl chr 2:131,751,848...131,780,349
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
EXP |
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
CTD |
PMID:29906468 |
|
NCBI chr18:64,589,613...64,622,169
Ensembl chr18:64,585,985...64,623,322
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
EXP |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:64,589,613...64,622,169
Ensembl chr18:64,585,985...64,623,322
|
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
EXP |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:29515023 |
|
NCBI chr 1:136,770,300...136,888,186
Ensembl chr 1:136,770,309...136,888,186
|
|
G |
Smad3 |
SMAD family member 3 |
decreases abundance |
EXP |
SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:23034213 |
|
NCBI chr 9:63,554,048...63,665,276
Ensembl chr 9:63,554,049...63,665,276
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594
|
|
G |
Cd68 |
CD68 antigen |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CXCL8 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases phosphorylation |
ISO |
AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Kcnab2 |
potassium voltage-gated channel, shaker-related subfamily, beta member 2 |
multiple interactions |
ISO |
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine |
CTD |
PMID:21296056 |
|
NCBI chr 4:152,475,201...152,561,991
Ensembl chr 4:152,475,199...152,562,367
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24079413 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Olr1 |
oxidized low density lipoprotein (lectin-like) receptor 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128
|
|
G |
Ptafr |
platelet-activating factor receptor |
affects binding multiple interactions |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] |
CTD |
PMID:16386258 |
|
NCBI chr 4:132,291,378...132,309,994
Ensembl chr 4:132,291,378...132,309,994
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Sele |
selectin, endothelial cell |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein |
CTD |
PMID:16386258 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Src |
Rous sarcoma oncogene |
multiple interactions increases phosphorylation |
ISO |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein] |
CTD |
PMID:24079413 |
|
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
Timp4 |
tissue inhibitor of metalloproteinase 4 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 6:115,221,405...115,229,166
Ensembl chr 6:115,218,853...115,229,166
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein |
CTD |
PMID:16386258 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Lipg |
lipase, endothelial |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:75,072,393...75,095,380
Ensembl chr18:75,072,393...75,094,334
|
|
|
G |
Lipc |
lipase, hepatic |
multiple interactions |
EXP |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508
|
|
G |
Lipg |
lipase, endothelial |
multiple interactions |
EXP |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr18:75,072,393...75,095,380
Ensembl chr18:75,072,393...75,094,334
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of ALOX12 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions increases expression |
ISO |
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor] Platelet Activating Factor results in increased expression of ALOX5 mRNA |
CTD |
PMID:8387780 PMID:10779545 PMID:16386258 |
|
NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein] |
CTD |
PMID:15149885 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CX3CR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 9:119,877,749...119,897,362
Ensembl chr 9:119,877,749...119,898,945
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions increases secretion |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CXCL8 protein] |
CTD |
PMID:15149885 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
ISO |
Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
ISO |
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of EGR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
ISO |
[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein] |
CTD |
PMID:23850278 |
|
NCBI chr 5:130,011,278...130,031,890
Ensembl chr 5:130,017,852...130,031,890
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions increases secretion |
ISO |
Platelet Activating Factor results in increased expression of IL1B mRNA [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein] |
CTD |
PMID:16386258 PMID:32830409 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
ISO |
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itgam |
integrin alpha M |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein] |
CTD |
PMID:9762784 PMID:11116075 |
|
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
|
|
G |
Ltb4r1 |
leukotriene B4 receptor 1 |
affects response to substance |
EXP |
LTB4R1 protein affects the susceptibility to Platelet Activating Factor |
CTD |
PMID:10934231 |
|
NCBI chr14:56,002,154...56,005,951
Ensembl chr14:56,003,419...56,005,951
|
|
G |
Mir149 |
microRNA 149 |
decreases expression multiple interactions |
ISO |
Platelet Activating Factor results in decreased expression of MIR149 mRNA [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA |
CTD |
PMID:32830409 |
|
NCBI chr 1:92,778,100...92,778,165
Ensembl chr 1:92,778,100...92,778,165
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of MMP13 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Myd88 |
myeloid differentiation primary response gene 88 |
multiple interactions increases expression |
ISO |
PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
EXP |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 3:27,237,153...27,299,112
Ensembl chr 3:27,237,114...27,338,757
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions increases degradation |
EXP |
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein] |
CTD |
PMID:10921504 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Olr1 |
oxidized low density lipoprotein (lectin-like) receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128
|
|
G |
Pla2g7 |
phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA] |
CTD |
PMID:21432021 |
|
NCBI chr17:43,879,009...43,923,093
Ensembl chr17:43,878,989...43,923,092
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Platelet Activating Factor results in decreased expression of PPARA mRNA |
CTD |
PMID:16386258 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions increases expression increases phosphorylation affects binding |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] Platelet Activating Factor results in increased expression of PTAFR mRNA Platelet Activating Factor results in increased phosphorylation of PTAFR protein bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] |
CTD |
PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 PMID:18205269 More...
|
|
NCBI chr 4:132,291,378...132,309,994
Ensembl chr 4:132,291,378...132,309,994
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pvt1 |
Pvt1 oncogene |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of PVT1 mRNA [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] |
CTD |
PMID:32830409 |
|
NCBI chr15:61,909,835...62,132,064
Ensembl chr15:61,888,639...62,249,945
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
ISO |
RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein] |
CTD |
PMID:11297424 |
|
NCBI chr 1:169,569,046...169,575,211
Ensembl chr 1:169,569,046...169,575,211
|
|
G |
Sele |
selectin, endothelial cell |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of SELE mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Sell |
selectin, lymphocyte |
multiple interactions increases secretion |
ISO |
Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein] |
CTD |
PMID:9762784 |
|
NCBI chr 1:163,889,556...163,908,354
Ensembl chr 1:163,889,551...163,911,750
|
|
G |
Selp |
selectin, platelet |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr 1:163,942,833...163,977,595
Ensembl chr 1:163,942,833...163,977,595
|
|
G |
Timp4 |
tissue inhibitor of metalloproteinase 4 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 6:115,221,405...115,229,166
Ensembl chr 6:115,218,853...115,229,166
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion multiple interactions increases expression |
ISO EXP |
Platelet Activating Factor results in increased secretion of TNF protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] Platelet Activating Factor results in increased expression of TNF mRNA Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA] |
CTD |
PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma |
RGD |
PMID:10452877 |
RGD:38508900 |
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
multiple interactions increases abundance |
EXP |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions |
ISO |
[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine |
CTD |
PMID:21439360 |
|
NCBI chr 2:110,094,401...110,145,158
Ensembl chr 2:110,093,042...110,144,905
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
multiple interactions increases abundance |
EXP |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine] |
CTD |
PMID:27469509 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
|
G |
Slc22a5 |
solute carrier family 22 (organic cation transporter), member 5 |
increases transport multiple interactions affects binding increases uptake |
ISO |
SLC22A5 protein results in increased transport of pivaloylcarnitine Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine] pivaloylcarnitine binds to SLC22A5 protein SLC22A5 protein results in increased uptake of pivaloylcarnitine |
CTD |
PMID:18762717 PMID:19539806 |
|
NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486
|
|
|
G |
Acacb |
acetyl-Coenzyme A carboxylase beta |
decreases expression |
ISO |
L-carnitine decreases expression of Acacb mRNA and protein in rat heart |
RGD |
PMID:30644033 |
RGD:329955369 |
NCBI chr 5:114,284,748...114,388,822
Ensembl chr 5:114,284,596...114,388,822
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
increases expression multiple interactions |
ISO |
L-carnitine increases expression of Cpt1a mRNA and protein in rat heart L-carnitine inhibits the reaction [sunitinib decreases expression of Cpt1a mRNA and protein in rat heart] |
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
increases expression multiple interactions |
ISO |
L-carnitine increases expression of Mlycd protein in rat heart L-carnitine inhibits the reaction [sunitinib increases expression of Mlycd protein in rat heart] |
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr 8:120,121,591...120,148,577
Ensembl chr 8:120,121,617...120,137,841
|
|
G |
Prkaa2 |
protein kinase, AMP-activated, alpha 2 catalytic subunit |
increases expression multiple interactions |
ISO |
L-carnitine increases expression of Ampka2 protein in rat serum and heart L-carnitine inhibits the reaction [sunitinib decreases expression of Ampka2 protein in rat serum and heart] |
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr 4:104,886,846...104,967,095
Ensembl chr 4:104,887,071...104,967,087
|
|
|
G |
Defb3 |
defensin beta 3 |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of and results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased secretion of DEFB4A protein] |
CTD |
PMID:27397760 PMID:28720485 |
|
NCBI chr 8:19,343,377...19,345,355
Ensembl chr 8:19,343,376...19,345,307
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]] |
CTD |
PMID:27397760 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR2 protein] |
CTD |
PMID:27397760 |
|
NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR4 protein] |
CTD |
PMID:28720485 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in increased secretion of TNF protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of TNF protein] |
CTD |
PMID:28720485 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [Cisplatin results in decreased activity of ACHE protein] |
CTD |
PMID:20932872 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:33580994 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein] |
CTD |
PMID:33580994 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein] |
CTD |
PMID:33580994 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein] |
CTD |
PMID:33580994 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein] |
CTD |
PMID:33580994 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] |
CTD |
PMID:33580994 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein] |
CTD |
PMID:33580994 |
|
NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein] |
CTD |
PMID:33580994 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Slc22a4 |
solute carrier family 22 (organic cation transporter), member 4 |
multiple interactions |
EXP ISO |
Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of and results in increased localization of Doxorubicin] Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of Doxorubicin] |
CTD |
PMID:37453608 |
|
NCBI chr11:53,873,941...53,920,866
Ensembl chr11:53,873,949...53,918,916
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein] |
CTD |
PMID:33580994 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ABCC4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Abi3bp |
ABI family member 3 binding protein |
increases expression |
ISO |
Betaine results in increased expression of ABI3BP mRNA |
CTD |
PMID:26391144 |
|
NCBI chr16:56,298,179...56,510,498
Ensembl chr16:56,298,241...56,510,498
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
multiple interactions |
ISO |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA |
CTD |
PMID:22648174 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Acacb |
acetyl-Coenzyme A carboxylase beta |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ACACB mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:114,284,748...114,388,822
Ensembl chr 5:114,284,596...114,388,822
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
multiple interactions |
ISO |
Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 mRNA]; Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 protein] |
CTD |
PMID:38108610 |
|
NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
ISO |
Betaine inhibits the reaction [Doxorubicin results in increased expression of ACTA2 mRNA] |
CTD |
PMID:37840533 PMID:38651543 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ADGRG2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr X:159,173,315...159,281,072
Ensembl chr X:159,173,686...159,281,066
|
|
G |
Adss2 |
adenylosuccinate synthase 2 |
decreases expression |
ISO |
Betaine results in decreased expression of ADSS2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:177,590,742...177,624,064
Ensembl chr 1:177,590,528...177,624,077
|
|
G |
Ahcy |
S-adenosylhomocysteine hydrolase |
decreases expression |
EXP ISO |
Betaine results in decreased expression of AHCY mRNA |
CTD |
PMID:22945834 PMID:26391144 |
|
NCBI chr 2:154,901,230...154,916,417
Ensembl chr 2:154,901,230...154,916,417
|
|
G |
Akip1 |
A kinase interacting protein 1 |
increases expression |
ISO |
Betaine results in increased expression of AKIP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:109,302,885...109,311,393
Ensembl chr 7:109,302,897...109,311,396
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
decreases expression |
ISO |
Betaine results in decreased expression of AKR1B1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of AKR1B7 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 6:34,389,297...34,400,072
Ensembl chr 6:34,389,269...34,400,077
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
Betaine inhibits the reaction [Doxorubicin results in decreased expression of ALB protein] |
CTD |
PMID:37840533 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2, mitochondrial |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein |
CTD |
PMID:20118189 |
|
NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887
|
|
G |
Apex1 |
apurinic/apyrimidinic endonuclease 1 |
decreases expression |
ISO |
Betaine results in decreased expression of APEX1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr14:51,162,406...51,164,645
Ensembl chr14:51,162,425...51,164,596
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein] |
CTD |
PMID:19635394 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Atp7b |
ATPase, copper transporting, beta polypeptide |
multiple interactions |
EXP |
ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased abundance of Copper]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:22945834 |
|
NCBI chr 8:22,482,799...22,550,347
Ensembl chr 8:22,482,801...22,550,321
|
|
G |
Axin1 |
axin 1 |
multiple interactions |
EXP |
[Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene |
CTD |
PMID:16868943 |
|
NCBI chr17:26,350,294...26,414,784
Ensembl chr17:26,357,662...26,414,785
|
|
G |
Bax |
BCL2-associated X protein |
decreases expression |
ISO |
Betaine results in decreased expression of BAX protein |
CTD |
PMID:25080425 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
affects binding increases expression |
ISO |
Betaine analog binds to BCL2 protein Betaine results in increased expression of BCL2 protein |
CTD |
PMID:25080425 PMID:25765238 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
ISO |
Betaine results in increased expression of BHLHE40 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:108,637,590...108,643,886
Ensembl chr 6:108,637,590...108,643,886
|
|
G |
Bhmt |
betaine-homocysteine methyltransferase |
increases metabolic processing |
ISO |
BHMT protein results in increased metabolism of Betaine |
CTD |
PMID:18230605 |
|
NCBI chr13:93,753,399...93,774,266
Ensembl chr13:93,753,183...93,774,469
|
|
G |
Brf1 |
BRF1, RNA polymerase III transcription initiation factor 90 kDa subunit |
multiple interactions |
ISO |
Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 mRNA]; Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 protein] |
CTD |
PMID:32418914 |
|
NCBI chr12:112,919,251...112,964,327
Ensembl chr12:112,923,705...112,964,324
|
|
G |
Cab39l |
calcium binding protein 39-like |
decreases expression |
ISO |
Betaine results in decreased expression of CAB39L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr14:59,678,400...59,786,353
Ensembl chr14:59,678,421...59,823,213
|
|
G |
Casp1 |
caspase 1 |
increases expression |
ISO |
Betaine results in increased expression of CASP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein] |
CTD |
PMID:24632105 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein; Betaine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] Betaine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Betaine inhibits the reaction [Carbon Tetrachloride results in increased activity of CAT protein]; Betaine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein] |
CTD |
PMID:12893363 PMID:20118189 PMID:24632105 PMID:36087182 PMID:37840533 PMID:38651543 More...
|
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccdc113 |
coiled-coil domain containing 113 |
increases expression |
ISO |
Betaine results in increased expression of CCDC113 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:96,260,684...96,285,516
Ensembl chr 8:96,260,713...96,285,518
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA |
CTD |
PMID:22648174 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
Betaine results in increased expression of CCL5 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
increases expression |
ISO |
Betaine results in increased expression of CCL6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
ISO |
Betaine results in decreased expression of CCNB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 9:70,314,971...70,328,836
Ensembl chr 9:70,314,974...70,328,829
|
|
G |
Cd44 |
CD44 antigen |
decreases expression |
ISO |
Betaine results in decreased expression of CD44 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cdc42ep2 |
CDC42 effector protein 2 |
decreases expression |
ISO |
Betaine results in decreased expression of CDC42EP2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:5,967,584...5,974,844
Ensembl chr19:5,965,664...5,974,844
|
|
G |
Cdh13 |
cadherin 13 |
decreases expression |
ISO |
Betaine results in decreased expression of CDH13 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:119,010,150...120,051,668
Ensembl chr 8:119,010,472...120,051,660
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CDK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
multiple interactions |
ISO |
Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA] |
CTD |
PMID:19642983 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Ces2c |
carboxylesterase 2C |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CES2C mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:105,573,700...105,581,115
Ensembl chr 8:105,573,700...105,581,115
|
|
G |
Ces3b |
carboxylesterase 3B |
increases expression |
ISO |
Betaine results in increased expression of CES3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:105,810,365...105,820,561
Ensembl chr 8:105,810,385...105,820,561
|
|
G |
Ckb |
creatine kinase, brain |
increases expression |
ISO |
Betaine results in increased expression of CKB mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:111,635,789...111,638,772
Ensembl chr12:111,635,795...111,638,772
|
|
G |
Cks1b |
CDC28 protein kinase 1b |
decreases expression |
ISO |
Betaine results in decreased expression of CKS1B mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:89,322,779...89,325,598
Ensembl chr 3:89,322,779...89,325,690
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CLCF1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr19:4,264,479...4,273,548
Ensembl chr19:4,264,292...4,273,544
|
|
G |
Cotl1 |
coactosin like F-actin binding protein 1 |
decreases expression |
ISO |
Betaine results in decreased expression of COTL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:120,535,953...120,567,318
Ensembl chr 8:120,535,961...120,567,283
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
multiple interactions decreases expression |
EXP |
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in decreased expression of CPT1A mRNA |
CTD |
PMID:22945834 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
decreases expression |
ISO |
Betaine results in decreased expression of CXCL16 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:70,345,215...70,350,810
Ensembl chr11:70,344,809...70,350,810
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP26A1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr19:37,686,186...37,689,984
Ensembl chr19:37,686,246...37,689,984
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2c55 |
cytochrome P450, family 2, subfamily c, polypeptide 55 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr19:38,995,384...39,031,134
Ensembl chr19:38,995,463...39,031,137
|
|
G |
Cyp2d9 |
cytochrome P450, family 2, subfamily d, polypeptide 9 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2D9 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of CYP2D9 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:82,336,578...82,341,028
Ensembl chr15:82,317,638...82,341,046
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein] Betaine promotes the reaction [Ethanol results in increased expression of CYP2E1] |
CTD |
PMID:20118189 PMID:21352821 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Cyp4a10 |
cytochrome P450, family 4, subfamily a, polypeptide 10 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of CYP4A10 protein |
CTD |
PMID:20118189 |
|
NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
increases expression |
ISO |
Betaine results in increased expression of CYSLTR1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr X:105,617,952...105,647,329
Ensembl chr X:105,617,952...105,647,285
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases expression |
ISO |
Betaine results in decreased expression of DAPK1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:60,749,506...60,911,005
Ensembl chr13:60,749,761...60,911,005
|
|
G |
Depp1 |
DEPP1 autophagy regulator |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of DEPP1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 6:116,627,645...116,629,808
Ensembl chr 6:116,627,570...116,629,755
|
|
G |
Dlx2 |
distal-less homeobox 2 |
increases expression |
ISO |
Betaine results in increased expression of DLX2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:71,373,752...71,377,095
Ensembl chr 2:71,373,752...71,377,098
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions increases expression |
EXP |
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in increased expression of DNMT1 mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3b |
DNA methyltransferase 3B |
decreases expression |
EXP |
Betaine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 2:153,491,332...153,529,650
Ensembl chr 2:153,491,370...153,529,650
|
|
G |
E2f8 |
E2F transcription factor 8 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of E2F8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:48,516,177...48,531,821
Ensembl chr 7:48,516,177...48,531,344
|
|
G |
Ect2 |
ect2 oncogene |
decreases expression |
ISO |
Betaine results in decreased expression of ECT2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:27,151,371...27,207,971
Ensembl chr 3:27,151,371...27,208,027
|
|
G |
Eef2k |
eukaryotic elongation factor-2 kinase |
increases expression |
ISO |
Betaine results in increased expression of EEF2K mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:120,442,080...120,506,441
Ensembl chr 7:120,442,054...120,506,673
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGFR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
ISO EXP |
Betaine results in increased expression of EGR1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGR1 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Elf3 |
E74-like factor 3 |
decreases expression |
ISO |
Betaine results in decreased expression of ELF3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:135,181,312...135,186,210
Ensembl chr 1:135,181,313...135,186,306
|
|
G |
Emc9 |
ER membrane protein complex subunit 9 |
increases expression |
ISO |
Betaine results in increased expression of EMC9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr14:55,818,976...55,822,832
Ensembl chr14:55,818,973...55,822,759
|
|
G |
Ephb6 |
Eph receptor B6 |
increases expression |
ISO |
Betaine results in increased expression of EPHB6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:41,581,940...41,597,445
Ensembl chr 6:41,582,416...41,597,443
|
|
G |
Esco2 |
establishment of sister chromatid cohesion N-acetyltransferase 2 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ESCO2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:66,056,476...66,071,418
Ensembl chr14:66,056,487...66,071,443
|
|
G |
F8 |
coagulation factor VIII |
multiple interactions increases secretion |
ISO |
Betaine affects the localization of and results in increased secretion of F8 protein; Betaine affects the localization of and results in increased secretion of F8 protein mutant form Betaine results in increased secretion of F8 protein; Betaine results in increased secretion of F8 protein mutant form |
CTD |
PMID:22973456 |
|
NCBI chr X:74,213,950...74,426,342
Ensembl chr X:74,216,321...74,426,221
|
|
G |
F9 |
coagulation factor IX |
increases secretion |
ISO |
Betaine results in increased secretion of F9 protein |
CTD |
PMID:22973456 |
|
NCBI chr X:59,044,675...59,076,120
Ensembl chr X:59,044,824...59,076,119
|
|
G |
Fabp5 |
fatty acid binding protein 5, epidermal |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of FABP5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 3:10,077,645...10,081,670
Ensembl chr 3:10,077,608...10,081,667
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter] |
CTD |
PMID:22648174 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Flrt3 |
fibronectin leucine rich transmembrane protein 3 |
increases expression |
ISO |
Betaine results in increased expression of FLRT3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:140,500,118...140,513,396
Ensembl chr 2:140,492,834...140,513,389
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
decreases expression |
ISO |
Betaine results in decreased expression of FXYD2 mRNA; Betaine results in decreased expression of FXYD2 mRNA alternative form |
CTD |
PMID:26391144 |
|
NCBI chr 9:45,311,007...45,321,576
Ensembl chr 9:45,310,967...45,321,576
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible 45 beta |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GADD45B mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:80,765,925...80,768,038
Ensembl chr10:80,765,907...80,768,038
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible 45 gamma |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GADD45G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:52,000,711...52,002,511
Ensembl chr13:52,000,714...52,002,504
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
ISO |
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:19294532 |
|
NCBI chr19:3,459,915...3,464,544
Ensembl chr19:3,459,915...3,464,544
|
|
G |
Gck |
glucokinase |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GCK mRNA |
CTD |
PMID:33549593 |
|
NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
|
|
G |
Gna14 |
guanine nucleotide binding protein, alpha 14 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GNA14 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr19:16,413,031...16,590,706
Ensembl chr19:16,413,126...16,588,184
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
increases expression multiple interactions |
ISO EXP |
Betaine results in increased expression of GPCPD1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GPCPD1 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr 2:132,371,002...132,420,173
Ensembl chr 2:132,371,002...132,429,649
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
EXP |
Betaine inhibits the reaction [Acetaminophen results in increased activity of GPT protein]; Betaine inhibits the reaction [sodium arsenite results in increased activity of GPT protein] |
CTD |
PMID:32081044 PMID:36087182 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
Betaine inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 mRNA]; Betaine inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 protein] |
CTD |
PMID:38108610 |
|
NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
|
|
G |
Gsta1 |
glutathione S-transferase, alpha 1 (Ya) |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTA5 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GSTA5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTM3 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 3:107,803,240...107,806,002
Ensembl chr 3:107,803,137...107,806,002
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
ISO |
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:19294532 |
|
NCBI chr 5:130,011,278...130,031,890
Ensembl chr 5:130,017,852...130,031,890
|
|
G |
H2az1 |
H2A.Z variant histone 1 |
decreases expression |
ISO |
Betaine results in decreased expression of H2AZ1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:137,570,248...137,572,683
Ensembl chr 3:137,570,248...137,572,683
|
|
G |
Hip1 |
huntingtin interacting protein 1 |
decreases expression |
ISO |
Betaine results in decreased expression of HIP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:135,435,350...135,574,167
Ensembl chr 5:135,435,385...135,573,974
|
|
G |
Hmgb2 |
high mobility group box 2 |
decreases expression |
ISO |
Betaine results in decreased expression of HMGB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:57,964,877...57,969,033
Ensembl chr 8:57,964,941...57,969,033
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO EXP |
Betaine inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA] Betaine inhibits the reaction [Acetaminophen results in increased expression of HMOX1 mRNA]; Betaine inhibits the reaction [Acetaminophen results in increased expression of HMOX1 protein] |
CTD |
PMID:32081044 PMID:37840533 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hspa5 |
heat shock protein 5 |
decreases expression |
EXP |
Betaine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
ISO |
Betaine results in increased expression of ID2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:25,143,798...25,146,091
Ensembl chr12:25,143,798...25,147,139
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
multiple interactions increases abundance |
EXP |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Betaine] |
CTD |
PMID:27469509 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA] |
CTD |
PMID:37840533 PMID:38651543 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of IRS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
|
|
G |
Irx4 |
Iroquois homeobox 4 |
decreases expression |
ISO |
Betaine results in decreased expression of IRX4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:73,407,708...73,417,741
Ensembl chr13:73,408,598...73,417,727
|
|
G |
Itga8 |
integrin alpha 8 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGA8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:12,111,443...12,306,755
Ensembl chr 2:12,111,443...12,306,733
|
|
G |
Itgb4 |
integrin beta 4 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGB4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr11:115,865,556...115,899,238
Ensembl chr11:115,865,535...115,899,238
|
|
G |
Jun |
jun proto-oncogene |
increases expression |
ISO |
Betaine results in increased expression of JUN mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Khdrbs3 |
KH domain containing, RNA binding, signal transduction associated 3 |
decreases expression |
ISO |
Betaine results in decreased expression of KHDRBS3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:68,800,155...68,973,064
Ensembl chr15:68,800,269...68,973,060
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
ISO |
Betaine results in increased expression of KIF1B mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:149,260,776...149,392,762
Ensembl chr 4:149,260,776...149,392,150
|
|
G |
Kif22 |
kinesin family member 22 |
decreases expression |
ISO |
Betaine results in decreased expression of KIF22 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:126,626,901...126,641,639
Ensembl chr 7:126,626,901...126,641,643
|
|
G |
Klf10 |
Kruppel-like transcription factor 10 |
increases expression |
ISO |
Betaine results in increased expression of KLF10 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:38,291,702...38,300,950
Ensembl chr15:38,291,707...38,300,950
|
|
G |
Krt2 |
keratin 2 |
increases expression |
ISO |
Betaine results in increased expression of KRT2 mRNA; Betaine results in increased expression of KRT2 protein |
CTD |
PMID:26391144 |
|
NCBI chr15:101,719,124...101,727,391
Ensembl chr15:101,719,124...101,726,604
|
|
G |
Krt4 |
keratin 4 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of KRT4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:101,826,970...101,833,170
Ensembl chr15:101,826,970...101,833,170
|
|
G |
Lars1 |
leucyl-tRNA synthetase 1 |
decreases expression |
ISO |
Betaine results in decreased expression of LARS1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr18:42,335,363...42,395,302
Ensembl chr18:42,335,363...42,395,259
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of LEPR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
|
|
G |
Lin9 |
lin-9 DREAM MuvB core complex component |
decreases expression |
ISO |
Betaine results in decreased expression of LIN9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:180,468,715...180,518,252
Ensembl chr 1:180,468,715...180,518,259
|
|
G |
Lratd1 |
LRAT domain containing 1 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRATD1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr12:14,197,599...14,202,039
Ensembl chr12:14,196,831...14,202,055
|
|
G |
Lrrc24 |
leucine rich repeat containing 24 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRRC24 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:76,599,476...76,606,373
Ensembl chr15:76,599,476...76,606,373
|
|
G |
Map4k1 |
mitogen-activated protein kinase kinase kinase kinase 1 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MAP4K1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:28,681,506...28,702,704
Ensembl chr 7:28,681,475...28,702,704
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
decreases stability multiple interactions |
ISO |
Betaine results in decreased stability of MARCHF6 protein Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein] |
CTD |
PMID:30545937 |
|
NCBI chr15:31,456,045...31,531,172
Ensembl chr15:31,456,037...31,531,199
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
decreases expression |
ISO |
Betaine results in decreased expression of MCM3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:20,873,188...20,890,536
Ensembl chr 1:20,873,192...20,890,536
|
|
G |
Mcm4 |
minichromosome maintenance complex component 4 |
decreases expression |
ISO |
Betaine results in decreased expression of MCM4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr16:15,441,761...15,455,264
Ensembl chr16:15,441,761...15,455,264
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:75,836,096...75,855,067
Ensembl chr 8:75,836,197...75,855,067
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM6 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:128,259,312...128,287,442
Ensembl chr 1:128,259,327...128,287,401
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
ISO |
Betaine results in decreased expression of MCM7 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:138,162,845...138,170,675
Ensembl chr 5:138,162,845...138,170,684
|
|
G |
Mical1 |
microtubule associated monooxygenase, calponin and LIM domain containing 1 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MICAL1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:41,351,693...41,363,026
Ensembl chr10:41,352,310...41,363,028
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MKI67 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
decreases expression |
ISO |
Betaine results in decreased expression of MTHFD1L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:3,918,282...4,117,081
Ensembl chr10:3,923,118...4,117,081
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Betaine results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:83,282,686...83,302,926
Ensembl chr 6:83,282,673...83,302,890
|
|
G |
Myc |
myelocytomatosis oncogene |
multiple interactions |
ISO |
Betaine inhibits the reaction [Diethylnitrosamine results in increased expression of MYC mRNA] |
CTD |
PMID:19642983 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Mycl |
v-myc avian myelocytomatosis viral oncogene lung carcinoma derived |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MYCL mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:122,889,414...122,896,278
Ensembl chr 4:122,889,445...122,896,278
|
|
G |
Nbl1 |
NBL1, DAN family BMP antagonist |
increases expression |
ISO |
Betaine results in increased expression of NBL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:138,809,602...138,820,437
Ensembl chr 4:138,809,595...138,820,304
|
|
G |
Nckipsd |
NCK interacting protein with SH3 domain |
decreases expression |
ISO |
Betaine results in decreased expression of NCKIPSD mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 9:108,685,515...108,696,044
Ensembl chr 9:108,685,567...108,696,043
|
|
G |
Ndrg4 |
N-myc downstream regulated gene 4 |
decreases expression |
ISO |
Betaine results in decreased expression of NDRG4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:96,403,602...96,441,584
Ensembl chr 8:96,403,608...96,441,747
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO EXP |
Betaine inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA]; Betaine inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 protein] Betaine inhibits the reaction [Acetaminophen results in increased expression of NFE2L2 mRNA]; Betaine inhibits the reaction [Acetaminophen results in increased expression of NFE2L2 protein] |
CTD |
PMID:32081044 PMID:37840533 PMID:38651543 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nlrp12 |
NLR family, pyrin domain containing 12 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of NLRP12 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:3,267,317...3,298,400
Ensembl chr 7:3,267,458...3,298,370
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Doxorubicin results in increased expression of NLRP3 mRNA] |
CTD |
PMID:37840533 PMID:38651543 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nupr1 |
nuclear protein transcription regulator 1 |
decreases expression |
ISO |
Betaine results in decreased expression of NUPR1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:126,222,418...126,224,642
Ensembl chr 7:126,222,421...126,230,033
|
|
G |
Ogg1 |
8-oxoguanine DNA-glycosylase 1 |
multiple interactions |
EXP |
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter] |
CTD |
PMID:22064374 |
|
NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
increases expression |
ISO |
Betaine results in increased expression of PCP4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr16:96,268,806...96,326,993
Ensembl chr16:96,268,806...96,326,993
|
|
G |
Pctp |
phosphatidylcholine transfer protein |
decreases expression |
ISO |
Betaine results in decreased expression of PCTP mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:89,873,370...89,893,720
Ensembl chr11:89,873,491...89,893,720
|
|
G |
Per2 |
period circadian clock 2 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of PER2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:91,343,699...91,387,028
Ensembl chr 1:91,343,704...91,387,046
|
|
G |
Pink1 |
PTEN induced putative kinase 1 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Doxorubicin results in increased expression of PINK1 protein] |
CTD |
PMID:38651543 |
|
NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618
|
|
G |
Pola2 |
polymerase (DNA directed), alpha 2 |
decreases expression |
ISO |
Betaine results in decreased expression of POLA2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:5,990,574...6,014,266
Ensembl chr19:5,990,570...6,014,230
|
|
G |
Pole2 |
polymerase (DNA directed), epsilon 2 (p59 subunit) |
decreases expression |
ISO |
Betaine results in decreased expression of POLE2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:69,248,547...69,274,979
Ensembl chr12:69,248,547...69,274,969
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein Betaine results in decreased expression of PPARA mRNA |
CTD |
PMID:20118189 PMID:22945834 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Ppp1r3g |
protein phosphatase 1, regulatory subunit 3G |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of PPP1R3G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:36,142,816...36,154,371
Ensembl chr13:36,142,822...36,154,371
|
|
G |
Ppp2ca |
protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform |
multiple interactions |
EXP |
Betaine inhibits the reaction [Ethanol results in decreased methylation of PPP2CA protein] |
CTD |
PMID:32492475 |
|
NCBI chr11:51,989,651...52,013,576
Ensembl chr11:51,989,508...52,018,605
|
|
G |
Prss23 |
serine protease 23 |
increases expression |
ISO |
Betaine results in increased expression of PRSS23 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:89,156,988...89,176,399
Ensembl chr 7:89,156,991...89,176,395
|
|
G |
Prss8 |
serine protease 8 (prostasin) |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of PRSS8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:127,524,889...127,529,266
Ensembl chr 7:127,524,888...127,529,276
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
EXP |
Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter] |
CTD |
PMID:19635394 |
|
NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression |
ISO |
Betaine results in decreased expression of PTGS1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284
|
|
G |
Ranbp3l |
RAN binding protein 3-like |
decreases expression |
ISO |
Betaine results in decreased expression of RANBP3L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:8,997,209...9,071,355
Ensembl chr15:8,997,433...9,067,417
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
Betaine inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Betaine inhibits the reaction [Fructose results in decreased activity of RELA protein] |
CTD |
PMID:25559852 PMID:38651543 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rfx4 |
regulatory factor X, 4 (influences HLA class II expression) |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RFX4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:84,591,895...84,742,402
Ensembl chr10:84,591,926...84,742,402
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RGS16 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:153,616,099...153,621,212
Ensembl chr 1:153,616,095...153,621,214
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
ISO |
Betaine results in increased expression of RGS2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:143,875,076...143,879,887
Ensembl chr 1:143,875,076...143,879,899
|
|
G |
Rrm2 |
ribonucleotide reductase M2 |
decreases expression multiple interactions |
ISO EXP |
Betaine results in decreased expression of RRM2 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of RRM2 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145
|
|
G |
S100a8 |
S100 calcium binding protein A8 (calgranulin A) |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of S100A8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
decreases expression |
ISO |
Betaine results in decreased expression of SCD1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Sectm1a |
secreted and transmembrane 1A |
increases expression |
ISO |
Betaine results in increased expression of SECTM1A mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:120,958,221...120,988,023
Ensembl chr11:120,958,233...120,972,046
|
|
G |
Serinc2 |
serine incorporator 2 |
decreases expression |
ISO |
Betaine results in decreased expression of SERINC2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:130,147,289...130,172,993
Ensembl chr 4:130,147,288...130,172,998
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
decreases expression |
ISO |
Betaine results in decreased expression of SERPINA3N mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:104,372,967...104,380,588
Ensembl chr12:104,372,988...104,380,588
|
|
G |
Slc16a6 |
solute carrier family 16 (monocarboxylic acid transporters), member 6 |
increases expression |
ISO |
Betaine results in increased expression of SLC16A6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:109,341,681...109,366,428
Ensembl chr11:109,341,681...109,364,424
|
|
G |
Slc22a27 |
solute carrier family 22, member 27 |
multiple interactions |
EXP |
Betaine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine] |
CTD |
PMID:20332632 |
|
NCBI chr19:7,841,753...7,943,899
Ensembl chr19:7,841,753...7,943,392
|
|
G |
Slc22a5 |
solute carrier family 22 (organic cation transporter), member 5 |
multiple interactions |
ISO |
Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:16928358 |
|
NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486
|
|
G |
Slc25a30 |
solute carrier family 25, member 30 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SLC25A30 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:75,994,986...76,024,477
Ensembl chr14:75,997,557...76,024,477
|
|
G |
Slc36a1 |
solute carrier family 36 (proton/amino acid symporter), member 1 |
increases uptake |
EXP |
SLC36A1 protein results in increased uptake of Betaine |
CTD |
PMID:18845132 |
|
NCBI chr11:55,095,148...55,127,156
Ensembl chr11:55,095,176...55,127,156
|
|
G |
Slc6a12 |
solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12 |
multiple interactions |
EXP |
Betaine inhibits the reaction [Lipopolysaccharides results in increased expression of SLC6A12 mRNA] |
CTD |
PMID:22053950 |
|
NCBI chr 6:121,319,533...121,342,732
Ensembl chr 6:121,320,035...121,342,734
|
|
G |
Slc6a20b |
solute carrier family 6 (neurotransmitter transporter), member 20B |
increases uptake |
EXP |
SLC6A20B protein results in increased uptake of Betaine |
CTD |
PMID:18845132 |
|
NCBI chr 9:123,422,888...123,461,603
Ensembl chr 9:123,419,865...123,461,630
|
|
G |
Slc6a9 |
solute carrier family 6 (neurotransmitter transporter, glycine), member 9 |
decreases expression |
ISO |
Betaine results in decreased expression of SLC6A9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:117,692,240...117,726,502
Ensembl chr 4:117,691,703...117,732,395
|
|
G |
Snx10 |
sorting nexin 10 |
decreases expression |
ISO |
Betaine results in decreased expression of SNX10 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:51,500,882...51,567,659
Ensembl chr 6:51,500,881...51,567,659
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SOCS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:95,219,765...95,253,176
Ensembl chr10:95,221,224...95,253,042
|
|
G |
Sostdc1 |
sclerostin domain containing 1 |
increases expression |
ISO |
Betaine results in increased expression of SOSTDC1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:36,364,168...36,368,451
Ensembl chr12:36,364,138...36,368,451
|
|
G |
Spc25 |
SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) |
decreases expression |
ISO |
Betaine results in decreased expression of SPC25 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:69,009,753...69,036,583
Ensembl chr 2:69,024,239...69,036,538
|
|
G |
Ssr4 |
signal sequence receptor, delta |
decreases expression |
ISO |
Betaine results in decreased expression of SSR4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr X:72,830,778...72,834,432
Ensembl chr X:72,830,634...72,834,436
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Betaine promotes the reaction [Isoproterenol results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:25080425 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Stmn1 |
stathmin 1 |
decreases expression |
ISO |
Betaine results in decreased expression of STMN1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:134,195,631...134,201,154
Ensembl chr 4:134,195,631...134,201,154
|
|
G |
Stxbp1 |
syntaxin binding protein 1 |
decreases expression |
ISO |
Betaine results in decreased expression of STXBP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:32,677,619...32,737,249
Ensembl chr 2:32,677,614...32,737,257
|
|
G |
Sult1e1 |
sulfotransferase family 1E, member 1 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of SULT1E1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:87,723,827...87,739,470
Ensembl chr 5:87,723,828...87,739,453
|
|
G |
Tab1 |
TGF-beta activated kinase 1/MAP3K7 binding protein 1 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Doxorubicin results in increased expression of TAB1 mRNA] |
CTD |
PMID:37840533 PMID:38651543 |
|
NCBI chr15:80,017,333...80,045,908
Ensembl chr15:80,017,328...80,045,908
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC mRNA]; Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC protein] |
CTD |
PMID:38108610 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
ISO |
Betaine results in increased expression of TGFB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:186,354,984...186,441,504
Ensembl chr 1:186,354,989...186,438,186
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Doxorubicin results in increased expression of TLR4 mRNA] |
CTD |
PMID:37840533 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA]; Betaine inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Betaine inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA] |
CTD |
PMID:22945834 PMID:36087182 PMID:37840533 PMID:38651543 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
decreases expression |
ISO |
Betaine results in decreased expression of TRIB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:15,841,726...15,866,963
Ensembl chr12:15,841,728...15,866,923
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Doxorubicin results in increased phosphorylation of TP53 protein] |
CTD |
PMID:38651543 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Ulk1 |
unc-51 like kinase 1 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ULK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:110,932,355...110,957,991
Ensembl chr 5:110,932,354...110,957,963
|
|
G |
Upk3bl |
uroplakin 3B-like |
decreases expression |
ISO |
Betaine results in decreased expression of UPK3BL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:136,086,114...136,105,549
Ensembl chr 5:136,083,346...136,093,180
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of USP2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 9:43,978,318...44,006,924
Ensembl chr 9:43,978,318...44,006,924
|
|
G |
Vnn1 |
vanin 1 |
multiple interactions |
EXP |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of VNN1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:23,770,586...23,781,242
Ensembl chr10:23,770,586...23,781,241
|
|
G |
Wnk4 |
WNK lysine deficient protein kinase 4 |
decreases expression |
ISO |
Betaine results in decreased expression of WNK4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:101,151,363...101,168,235
Ensembl chr11:101,151,393...101,168,235
|
|
G |
Ybx2 |
Y box protein 2 |
decreases expression |
ISO |
Betaine results in decreased expression of YBX2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:69,826,652...69,832,430
Ensembl chr11:69,826,622...69,832,431
|
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif 4 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 1:171,077,698...171,089,836
Ensembl chr 1:171,077,990...171,088,206
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif 5 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein] |
CTD |
PMID:32417162 |
|
NCBI chr16:85,655,045...85,698,013
Ensembl chr16:85,653,061...85,698,716
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:32417162 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:32417162 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:32417162 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:32417162 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:32417162 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Acadl |
acyl-Coenzyme A dehydrogenase, long-chain |
increases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of ACADL mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 1:66,869,998...66,902,468
Ensembl chr 1:66,869,998...66,902,436
|
|
G |
Acadm |
acyl-Coenzyme A dehydrogenase, medium chain |
decreases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of ACADM mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 3:153,627,990...153,650,280
Ensembl chr 3:153,627,994...153,650,269
|
|
G |
Acadvl |
acyl-Coenzyme A dehydrogenase, very long chain |
affects expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACADVL mRNA |
CTD |
PMID:32389661 |
|
NCBI chr11:69,901,009...69,906,254
Ensembl chr11:69,901,009...69,906,237
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
affects expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACOX1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1b, muscle |
decreases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1B mRNA |
CTD |
PMID:32389661 |
|
NCBI chr15:89,300,608...89,310,065
Ensembl chr15:89,300,608...89,310,066
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
decreases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1C mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 7:44,607,907...44,624,304
Ensembl chr 7:44,608,796...44,624,275
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of HK1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase, isoenzyme 1 |
increases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of PDK1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 2:71,703,398...71,734,202
Ensembl chr 2:71,703,568...71,734,202
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARA mRNA |
CTD |
PMID:32389661 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
decreases expression |
ISO EXP |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:27559315 PMID:32389661 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ppargc1b |
peroxisome proliferative activated receptor, gamma, coactivator 1 beta |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARGC1B mRNA |
CTD |
PMID:27559315 |
|
NCBI chr18:61,424,516...61,533,846
Ensembl chr18:61,431,207...61,533,502
|
|
G |
Slc22a5 |
solute carrier family 22 (organic cation transporter), member 5 |
increases uptake |
ISO |
SLC22A5 protein results in increased uptake of 3-(2,2,2-trimethylhydrazine)propionate |
CTD |
PMID:18981167 |
|
NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
increases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of SLC2A4 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc5a2 |
solute carrier family 5 (sodium/glucose cotransporter), member 2 |
affects expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of SLC5A2 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 7:127,864,855...127,871,602
Ensembl chr 7:127,864,829...127,871,602
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of TFAM mRNA |
CTD |
PMID:27559315 |
|
NCBI chr10:71,061,298...71,074,157
Ensembl chr10:71,061,294...71,074,110
|
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO EXP |
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein] |
CTD |
PMID:29211853 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO EXP |
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein] |
CTD |
PMID:29211853 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO EXP |
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein] |
CTD |
PMID:29211853 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
EXP ISO |
trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein] ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein] |
CTD |
PMID:30208301 |
|
NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein] [trigonelline co-treated with Cisplatin] results in increased expression of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein |
CTD |
PMID:31935362 PMID:33148531 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein] [trigonelline co-treated with Cisplatin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein |
CTD |
PMID:31935362 PMID:33148531 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Becn1 |
beclin 1, autophagy related |
multiple interactions |
EXP ISO |
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in decreased expression of BECN1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein] |
CTD |
PMID:30208301 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
EXP ISO |
trigonelline results in increased activity of CASP3 protein [trigonelline co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein] |
CTD |
PMID:26593444 PMID:31935362 PMID:33148531 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
EXP |
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of CD36 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of CD36 protein] |
CTD |
PMID:30208301 |
|
NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[trigonelline co-treated with ferric citrate] results in increased expression of DDIT3 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein] |
CTD |
PMID:33148531 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases phosphorylation multiple interactions |
ISO |
trigonelline results in decreased phosphorylation of EGFR protein trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:33148531 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
multiple interactions |
EXP |
trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:30208301 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Fth1 |
ferritin heavy polypeptide 1 |
multiple interactions |
ISO |
[trigonelline co-treated with ferric citrate] results in increased expression of FTH1 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
|
|
G |
Ftl1 |
ferritin light polypeptide 1 |
multiple interactions |
ISO |
[trigonelline co-treated with ferric citrate] results in increased expression of FTL mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA] |
CTD |
PMID:24015256 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Hexb |
hexosaminidase B |
multiple interactions |
ISO |
trigonelline inhibits the reaction [iodixanol results in increased secretion of HEXB protein] |
CTD |
PMID:34774977 |
|
NCBI chr13:97,312,839...97,334,865
Ensembl chr13:97,312,839...97,334,865
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression |
ISO |
trigonelline results in decreased expression of HMOX1 mRNA; trigonelline results in decreased expression of HMOX1 protein |
CTD |
PMID:33148531 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions |
EXP |
trigonelline inhibits the reaction [Palmitic Acid results in increased expression of HSPA5 protein] |
CTD |
PMID:30208301 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein] |
CTD |
PMID:31935362 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL6 protein] |
CTD |
PMID:31935362 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions |
EXP |
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of INS1 protein] |
CTD |
PMID:30208301 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
multiple interactions |
EXP |
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]; trigonelline inhibits the reaction [INS2 protein affects the abundance of angiotensin I (1-7)] |
CTD |
PMID:29211853 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
[trigonelline co-treated with ferric citrate] results in decreased expression of KEAP1 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Lepr |
leptin receptor |
affects abundance |
EXP |
LEPR affects the abundance of trigonelline |
CTD |
PMID:20567778 |
|
NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] trigonelline results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:33148531 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] trigonelline results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:33148531 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mas1 |
MAS1 oncogene |
multiple interactions |
EXP ISO |
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA] |
CTD |
PMID:29211853 |
|
NCBI chr17:13,056,981...13,087,037
Ensembl chr17:13,059,966...13,087,030
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of MTOR protein] |
CTD |
PMID:30208301 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Myc |
myelocytomatosis oncogene |
decreases expression |
EXP |
trigonelline results in decreased expression of MYC mRNA |
CTD |
PMID:26593444 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions decreases phosphorylation |
ISO EXP |
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]; trigonelline inhibits the reaction [ferric citrate affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Cisplatin]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]]; trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein] trigonelline results in decreased phosphorylation of NFE2L2 protein |
CTD |
PMID:24015256 PMID:29211853 PMID:29959986 PMID:33148531 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions decreases expression |
ISO |
trigonelline inhibits the reaction [ferric citrate results in increased expression of NQO1 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA] trigonelline results in decreased expression of NQO1 mRNA; trigonelline results in decreased expression of NQO1 protein |
CTD |
PMID:24015256 PMID:29959986 PMID:33148531 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions |
EXP ISO |
trigonelline inhibits the reaction [Palmitic Acid results in increased cleavage of PARP1 protein] [trigonelline co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein |
CTD |
PMID:30208301 PMID:33148531 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
ISO |
trigonelline inhibits the reaction [iodixanol results in increased phosphorylation of PLCG1 protein] |
CTD |
PMID:34774977 |
|
NCBI chr 2:160,573,230...160,617,680
Ensembl chr 2:160,573,220...160,617,680
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
EXP |
trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PLIN1 protein] |
CTD |
PMID:30208301 |
|
NCBI chr 7:79,370,912...79,382,652
Ensembl chr 7:79,369,966...79,382,651
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
ISO EXP |
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein] trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of PPARG protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein] |
CTD |
PMID:30208301 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
affects abundance |
EXP |
SLCO1A1 protein affects the abundance of trigonelline |
CTD |
PMID:21561886 |
|
NCBI chr 6:141,853,007...141,892,688
Ensembl chr 6:141,853,008...141,892,688
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO EXP |
trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SQSTM1 protein] trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SQSTM1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SQSTM1 protein] |
CTD |
PMID:30208301 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP ISO |
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SREBF1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein] ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein] |
CTD |
PMID:30208301 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein] |
CTD |
PMID:31935362 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Acetylcarnitine inhibits the reaction [Dexamethasone results in increased activity of ACHE protein] |
CTD |
PMID:21986892 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Apex1 |
apurinic/apyrimidinic endonuclease 1 |
increases expression |
ISO |
Acetylcarnitine results in increased expression of APEX1 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr14:51,162,406...51,164,645
Ensembl chr14:51,162,425...51,164,596
|
|
G |
Atp6v1f |
ATPase, H+ transporting, lysosomal V1 subunit F |
increases expression |
ISO |
Acetylcarnitine results in increased expression of ATP6V1F mRNA |
CTD |
PMID:14654561 |
|
NCBI chr 6:29,467,782...29,470,508
Ensembl chr 6:29,467,717...29,470,511
|
|
G |
C1qa |
complement component 1, q subcomponent, alpha polypeptide |
decreases expression |
EXP |
Acetylcarnitine results in decreased expression of C1QA mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114
|
|
G |
C4b |
complement C4B (Chido blood group) |
decreases expression |
EXP |
Acetylcarnitine results in decreased expression of C4B mRNA |
CTD |
PMID:19555370 |
|
NCBI chr17:34,947,249...34,962,876
Ensembl chr17:34,947,354...34,962,856
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of CASP3 mRNA] |
CTD |
PMID:20067779 PMID:29278859 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP9 protein] |
CTD |
PMID:29278859 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of CAT mRNA] |
CTD |
PMID:20067779 PMID:26349760 PMID:29278859 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Col2a1 |
collagen, type II, alpha 1 |
multiple interactions |
ISO |
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Acetylcarnitine |
CTD |
PMID:24709313 |
|
NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576
|
|
G |
Cs |
citrate synthase |
decreases activity |
ISO |
Acetylcarnitine results in decreased activity of CS protein |
CTD |
PMID:9821151 |
|
NCBI chr10:128,173,596...128,198,351
Ensembl chr10:128,173,603...128,198,348
|
|
G |
Csprs |
component of Sp100-rs |
decreases expression |
EXP |
Acetylcarnitine results in decreased expression of CSPRS mRNA |
CTD |
PMID:19555370 |
|
|
|
G |
Ctss |
cathepsin S |
decreases expression |
EXP |
Acetylcarnitine results in decreased expression of CTSS mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 3:95,434,097...95,463,716
Ensembl chr 3:95,434,097...95,463,714
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
EXP |
Acetylcarnitine results in decreased expression of CXCL14 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr13:56,436,456...56,444,624
Ensembl chr13:56,436,456...56,444,364
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of EGR1 mRNA] |
CTD |
PMID:20067779 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
EXP |
Acetylcarnitine results in decreased expression of GFAP mRNA |
CTD |
PMID:19555370 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Gsr |
glutathione reductase |
multiple interactions |
EXP |
Acetylcarnitine inhibits the reaction [Acetaminophen results in decreased expression of GSR protein] |
CTD |
PMID:26265018 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in decreased expression of GSTP1 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hmox2 |
heme oxygenase 2 |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX2 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr16:4,544,225...4,584,606
Ensembl chr16:4,544,225...4,584,606
|
|
G |
Hspb1 |
heat shock protein 1 |
decreases expression |
ISO |
Acetylcarnitine results in decreased expression of HSPB1 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
increases abundance multiple interactions |
EXP |
IDH2 protein mutant form results in increased abundance of Acetylcarnitine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Acetylcarnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] |
CTD |
PMID:29278859 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] |
CTD |
PMID:29278859 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Lyz1 |
lysozyme 1 |
decreases expression |
EXP |
Acetylcarnitine results in decreased expression of LYZ1 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr10:117,123,700...117,128,773
Ensembl chr10:117,123,702...117,128,773
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases expression |
ISO |
Acetylcarnitine results in increased expression of MGST1 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr 6:138,117,525...138,133,753
Ensembl chr 6:138,117,314...138,133,753
|
|
G |
mt-Co1 |
cytochrome c oxidase I, mitochondrial |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of COX1 mRNA] |
CTD |
PMID:20067779 |
|
NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Cisplatin results in decreased expression of NGF protein] |
CTD |
PMID:14654561 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Nos1 |
nitric oxide synthase 1, neuronal |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS1 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr 5:118,004,904...118,096,905
Ensembl chr 5:117,919,097...118,096,905
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS2 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Pah |
phenylalanine hydroxylase |
decreases expression |
EXP |
Acetylcarnitine results in decreased expression of PAH mRNA |
CTD |
PMID:19555370 |
|
NCBI chr10:87,357,657...87,419,999
Ensembl chr10:87,357,657...87,419,998
|
|
G |
Pink1 |
PTEN induced putative kinase 1 |
multiple interactions |
EXP |
Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PINK1] |
CTD |
PMID:25464205 |
|
NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
increases expression multiple interactions |
ISO |
Acetylcarnitine results in increased expression of PPARGC1A protein [Acetylcarnitine co-treated with Thioctic Acid] results in increased expression of PPARGC1A protein |
CTD |
PMID:20414966 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
EXP |
Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PRKN] |
CTD |
PMID:25464205 |
|
NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248
|
|
G |
Psmb6 |
proteasome (prosome, macropain) subunit, beta type 6 |
increases expression |
ISO |
Acetylcarnitine results in increased expression of PSMB6 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr11:70,416,116...70,418,684
Ensembl chr11:70,416,193...70,418,684
|
|
G |
Ptma |
prothymosin alpha |
increases expression |
ISO |
Acetylcarnitine results in increased expression of PTMA mRNA |
CTD |
PMID:14654561 |
|
NCBI chr 1:86,454,442...86,458,434
Ensembl chr 1:86,454,448...86,458,434
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of RELA protein] |
CTD |
PMID:29278859 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rps17 |
ribosomal protein S17 |
increases expression |
ISO |
Acetylcarnitine results in increased expression of RPS17 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr 7:80,992,481...80,994,982
Ensembl chr 7:80,992,480...80,995,002
|
|
G |
Skap2 |
src family associated phosphoprotein 2 |
decreases expression |
EXP |
Acetylcarnitine results in decreased expression of SKAP2 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 6:51,836,145...51,989,529
Ensembl chr 6:51,834,402...51,989,529
|
|
G |
Slc22a27 |
solute carrier family 22, member 27 |
multiple interactions |
EXP |
Acetylcarnitine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine] |
CTD |
PMID:20332632 |
|
NCBI chr19:7,841,753...7,943,899
Ensembl chr19:7,841,753...7,943,392
|
|
G |
Slc25a20 |
solute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 20 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein] |
CTD |
PMID:23402788 |
|
NCBI chr 9:108,539,335...108,561,841
Ensembl chr 9:108,539,287...108,561,840
|
|
G |
Snca |
synuclein, alpha |
multiple interactions |
ISO |
[Acetylcarnitine co-treated with Thioctic Acid] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Acetylcarnitine inhibits the reaction [Rotenone results in increased expression of SNCA protein] |
CTD |
PMID:20414966 |
|
NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839
|
|
G |
Tnni3 |
troponin I, cardiac 3 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Cisplatin results in increased expression of TNNI3 protein] |
CTD |
PMID:21034734 |
|
NCBI chr 7:4,521,304...4,526,228
Ensembl chr 7:4,521,304...4,527,228
|
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
increases abundance multiple interactions |
EXP |
IDH2 protein mutant form results in increased abundance of butyrylcarnitine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of butyrylcarnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
|
G |
Crot |
carnitine O-octanoyltransferase |
increases chemical synthesis |
EXP |
CROT protein results in increased chemical synthesis of octanoylcarnitine |
CTD |
PMID:6838215 |
|
NCBI chr 5:9,016,033...9,047,926
Ensembl chr 5:9,016,033...9,047,324
|
|
G |
Slc22a27 |
solute carrier family 22, member 27 |
multiple interactions |
EXP |
octanoylcarnitine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine] |
CTD |
PMID:20332632 |
|
NCBI chr19:7,841,753...7,943,899
Ensembl chr19:7,841,753...7,943,392
|
|
|
G |
Col2a1 |
collagen, type II, alpha 1 |
multiple interactions |
ISO |
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Palmitoylcarnitine |
CTD |
PMID:24709313 |
|
NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576
|
|
G |
Gls |
glutaminase |
increases chemical synthesis |
ISO |
GLS protein results in increased chemical synthesis of Palmitoylcarnitine |
CTD |
PMID:31040181 |
|
NCBI chr 1:52,202,608...52,274,168
Ensembl chr 1:52,202,607...52,272,391
|
|
G |
Ppp3r1 |
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) |
decreases metabolic processing |
EXP |
PPP3R1 gene mutant form results in decreased metabolism of Palmitoylcarnitine |
CTD |
PMID:19700627 |
|
NCBI chr11:17,109,298...17,150,380
Ensembl chr11:17,109,263...17,150,375
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
increases chemical synthesis |
ISO |
PRKAA1 protein results in increased chemical synthesis of Palmitoylcarnitine |
CTD |
PMID:31040181 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
|
G |
App |
amyloid beta precursor protein |
increases abundance multiple interactions |
ISO EXP |
APP protein mutant form results in increased abundance of propionylcarnitine [APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of propionylcarnitine] |
CTD |
PMID:39172838 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions decreases abundance |
ISO |
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of propionylcarnitine] |
CTD |
PMID:39172838 |
|
NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
EXP |
[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine |
CTD |
PMID:39172838 |
|
NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973
|
|
|
G |
Aifm1 |
apoptosis-inducing factor, mitochondrion-associated 1 |
multiple interactions |
ISO |
[perifosine co-treated with Butyrates] results in increased secretion of AIFM1 protein; [perifosine co-treated with trichostatin A] results in increased secretion of AIFM1 protein; [perifosine co-treated with vorinostat] results in increased secretion of AIFM1 protein |
CTD |
PMID:15781658 |
|
NCBI chr X:47,563,821...47,602,440
Ensembl chr X:47,563,821...47,602,440
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
[perifosine co-treated with Butyrates] results in decreased activity of AKT1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of AKT1 protein; [perifosine co-treated with Vorinostat] results in decreased activity of AKT1 protein; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Butyrates]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with trichostatin A]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Vorinostat]; perifosine inhibits the reaction [cyadox results in increased phosphorylation of AKT1 protein] perifosine results in decreased phosphorylation of AKT1 protein [perifosine co-treated with temsirolimus] results in decreased activity of AKT1 protein |
CTD |
PMID:15781658 PMID:21267448 PMID:30265530 PMID:31445927 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
[perifosine co-treated with Butyrates] results in decreased expression of BAK1 protein; [perifosine co-treated with trichostatin A] results in decreased expression of BAK1 protein; [perifosine co-treated with vorinostat] results in decreased expression of BAK1 protein |
CTD |
PMID:15781658 |
|
NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
[perifosine co-treated with Butyrates] results in increased activity of BAX protein; [perifosine co-treated with trichostatin A] results in increased activity of BAX protein; [perifosine co-treated with vorinostat] results in increased activity of BAX protein |
CTD |
PMID:15781658 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression |
ISO |
[perifosine co-treated with Butyrates] results in increased activity of CASP3 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP3 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP3 protein perifosine results in decreased expression of CASP3 protein |
CTD |
PMID:15781658 PMID:25416439 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases expression |
ISO |
[perifosine co-treated with Butyrates] results in increased activity of CASP8 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP8 protein; [perifosine co-treated with Vorinostat] results in increased activity of CASP8 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form] |
CTD |
PMID:15781658 PMID:32587277 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
ISO |
perifosine inhibits the reaction [Mitomycin results in increased expression of CDKN1A protein] |
CTD |
PMID:34624459 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
[perifosine co-treated with Butyrates] affects the localization of CYCS protein; [perifosine co-treated with trichostatin A] affects the localization of CYCS protein; [perifosine co-treated with vorinostat] affects the localization of CYCS protein |
CTD |
PMID:15781658 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
perifosine inhibits the reaction [cyadox results in increased expression of EGF]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of EGF] |
CTD |
PMID:30265530 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Fas |
Fas cell surface death receptor |
affects response to substance |
ISO |
perifosine affects the susceptibility to FAS protein |
CTD |
PMID:31445927 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO EXP |
[perifosine co-treated with cyadox] results in increased expression of FOXO1 mRNA; [perifosine co-treated with Hydrogen Peroxide] results in increased expression of FOXO1 mRNA perifosine inhibits the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein] |
CTD |
PMID:30265530 PMID:33078829 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
perifosine inhibits the reaction [Mitomycin results in increased activity of GLB1 protein] |
CTD |
PMID:34624459 |
|
NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966
|
|
G |
Lat2 |
linker for activation of T cells family, member 2 |
multiple interactions decreases response to substance decreases expression |
ISO |
ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form] LAT2 protein results in decreased susceptibility to perifosine |
CTD |
PMID:23001822 PMID:32587277 |
|
NCBI chr 5:134,628,957...134,648,637
Ensembl chr 5:134,628,876...134,643,879
|
|
G |
Map2k1 |
mitogen-activated protein kinase kinase 1 |
multiple interactions |
ISO |
MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat] |
CTD |
PMID:15781658 |
|
NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
[perifosine co-treated with Butyrates] results in decreased activity of MAPK1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK1 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK1 protein |
CTD |
PMID:15781658 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
[perifosine co-treated with Butyrates] results in decreased activity of MAPK3 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK3 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK3 protein |
CTD |
PMID:15781658 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[perifosine co-treated with Butyrates] results in increased activity of MAPK8 protein; [perifosine co-treated with trichostatin A] results in increased activity of MAPK8 protein; [perifosine co-treated with vorinostat] results in increased activity of MAPK8 protein |
CTD |
PMID:15781658 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[perifosine co-treated with temsirolimus] results in decreased activity of MTOR protein |
CTD |
PMID:21267448 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases cleavage multiple interactions |
ISO |
perifosine results in increased cleavage of PARP1 protein benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein] |
CTD |
PMID:32587277 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance |
ISO |
perifosine results in increased susceptibility to TNF protein |
CTD |
PMID:31445927 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA]; perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] |
CTD |
PMID:30265530 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
increases secretion |
EXP |
ABCB11 protein results in increased secretion of Phosphatidylcholines |
CTD |
PMID:14570929 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
affects export affects transport |
ISO |
ABCB1 protein affects the export of Phosphatidylcholines ABCB1 protein affects the transport of Phosphatidylcholines |
CTD |
PMID:11147995 PMID:11745043 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
affects transport affects export |
EXP ISO |
ABCB4 protein affects the transport of Phosphatidylcholines ABCB4 protein affects the export of Phosphatidylcholines |
CTD |
PMID:11745043 PMID:15696852 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Acat1 |
acetyl-Coenzyme A acetyltransferase 1 |
decreases activity |
ISO |
Phosphatidylcholines results in decreased activity of ACAT1 protein |
CTD |
PMID:12559476 |
|
NCBI chr 9:53,491,822...53,521,650
Ensembl chr 9:53,491,822...53,521,682
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
EXP |
Phosphatidylcholines results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:23911798 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions increases abundance |
EXP ISO |
PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines] |
CTD |
PMID:29416063 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Aifm1 |
apoptosis-inducing factor, mitochondrion-associated 1 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of AIFM1 protein |
CTD |
PMID:21695227 |
|
NCBI chr X:47,563,821...47,602,440
Ensembl chr X:47,563,821...47,602,440
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide] |
CTD |
PMID:17964426 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
As3mt |
arsenite methyltransferase |
affects metabolic processing |
EXP |
AS3MT gene mutant form affects the metabolism of Phosphatidylcholines |
CTD |
PMID:27591999 |
|
NCBI chr19:46,695,124...46,729,538
Ensembl chr19:46,695,897...46,729,538
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of BAX protein |
CTD |
PMID:21695227 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of BCL2 protein |
CTD |
PMID:21695227 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
increases abundance |
EXP |
BMAL1 gene mutant form results in increased abundance of Phosphatidylcholines |
CTD |
PMID:27056296 |
|
NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP3 protein |
CTD |
PMID:21695227 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP8 protein |
CTD |
PMID:21695227 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP9 protein |
CTD |
PMID:21695227 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
EXP |
Phosphatidylcholines results in increased expression of CCL2 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CCND1 protein |
CTD |
PMID:21695227 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
Phosphatidylcholines promotes the reaction [rubitecan results in decreased expression of CCNE1 protein] |
CTD |
PMID:21695227 |
|
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CDK2 protein |
CTD |
PMID:21695227 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1A protein |
CTD |
PMID:21695227 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1B protein |
CTD |
PMID:21695227 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases expression |
EXP |
Phosphatidylcholines results in decreased expression of CES1D mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
multiple interactions |
ISO |
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
affects binding decreases activity |
ISO |
CRP protein binds to Phosphatidylcholines Phosphatidylcholines results in decreased activity of CRP protein |
CTD |
PMID:16962105 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects activity |
ISO |
Phosphatidylcholines affects the activity of CYP1A2 protein |
CTD |
PMID:15966743 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
increases activity |
ISO |
Phosphatidylcholines results in increased activity of CYP7A1 protein |
CTD |
PMID:12559476 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Enpp7 |
ectonucleotide pyrophosphatase/phosphodiesterase 7 |
increases hydrolysis |
ISO |
ENPP7 protein results in increased hydrolysis of Phosphatidylcholines |
CTD |
PMID:12885774 |
|
NCBI chr11:118,879,007...118,884,047
Ensembl chr11:118,879,014...118,884,047
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines |
CTD |
PMID:18723500 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fgf15 |
fibroblast growth factor 15 |
decreases abundance |
EXP |
FGF19 protein results in decreased abundance of Phosphatidylcholines |
CTD |
PMID:29416063 |
|
NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] |
CTD |
PMID:22433871 |
|
NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
increases activity |
ISO |
Phosphatidylcholines results in increased activity of HMGCR protein |
CTD |
PMID:12559476 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases degradation |
EXP |
IGF1 protein results in increased degradation of Phosphatidylcholines |
CTD |
PMID:2120207 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Il10 |
interleukin 10 |
increases expression |
EXP |
Phosphatidylcholines results in increased expression of IL10 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
Phosphatidylcholines results in increased expression of IL1B mRNA Phosphatidylcholines results in increased expression of and results in increased secretion of IL1B protein |
CTD |
PMID:23911798 PMID:30958839 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
increases expression |
EXP |
Phosphatidylcholines results in increased expression of IL6 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Lep |
leptin |
decreases expression |
EXP |
Phosphatidylcholines results in decreased expression of LEP mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lipc |
lipase, hepatic |
multiple interactions increases abundance |
EXP |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPC gene mutant form results in increased abundance of Phosphatidylcholines |
CTD |
PMID:24777581 |
|
NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508
|
|
G |
Lipe |
lipase, hormone sensitive |
increases expression |
EXP |
Phosphatidylcholines results in increased expression of LIPE mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135
|
|
G |
Lipg |
lipase, endothelial |
multiple interactions increases abundance |
EXP |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPG gene mutant form results in increased abundance of Phosphatidylcholines |
CTD |
PMID:24777581 |
|
NCBI chr18:75,072,393...75,095,380
Ensembl chr18:75,072,393...75,094,334
|
|
G |
Ltf |
lactotransferrin |
multiple interactions |
EXP |
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:16141546 |
|
NCBI chr 9:110,848,360...110,871,834
Ensembl chr 9:110,848,339...110,871,835
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] |
CTD |
PMID:22433871 |
|
NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases abundance |
EXP |
NR0B2 protein results in decreased abundance of Phosphatidylcholines |
CTD |
PMID:29416063 |
|
NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
EXP |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Phosphatidylcholines |
CTD |
PMID:29515023 |
|
NCBI chr 1:136,770,300...136,888,186
Ensembl chr 1:136,770,309...136,888,186
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 |
multiple interactions increases secretion |
ISO |
PAFAH1B1 protein promotes the reaction [Terbutaline results in increased secretion of Phosphatidylcholines]; PAFAH1B1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of Phosphatidylcholines] PAFAH1B1 protein results in increased secretion of Phosphatidylcholines |
CTD |
PMID:12013527 |
|
NCBI chr11:74,564,775...74,615,210
Ensembl chr11:74,564,775...74,615,496
|
|
G |
Pafah2 |
platelet-activating factor acetylhydrolase 2 |
multiple interactions |
ISO |
PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] |
CTD |
PMID:22433871 |
|
NCBI chr 4:134,123,631...134,154,723
Ensembl chr 4:134,123,631...134,154,724
|
|
G |
Pcyt1a |
phosphate cytidylyltransferase 1, choline, alpha isoform |
multiple interactions |
ISO |
PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines] |
CTD |
PMID:18930839 |
|
NCBI chr16:32,249,739...32,293,883
Ensembl chr16:32,249,739...32,293,888
|
|
G |
Pemt |
phosphatidylethanolamine N-methyltransferase |
multiple interactions |
ISO EXP |
PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines] |
CTD |
PMID:29416063 |
|
NCBI chr11:59,861,440...59,937,394
Ensembl chr11:59,861,440...59,937,315
|
|
G |
Plin1 |
perilipin 1 |
increases expression |
EXP |
Phosphatidylcholines results in increased expression of PLIN1 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 7:79,370,912...79,382,652
Ensembl chr 7:79,369,966...79,382,651
|
|
G |
Plpp6 |
phospholipid phosphatase 6 |
multiple interactions increases chemical synthesis |
ISO |
PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines] |
CTD |
PMID:18930839 |
|
NCBI chr19:28,941,320...28,944,201
Ensembl chr19:28,941,353...28,944,211
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
decreases expression |
EXP |
Phosphatidylcholines results in decreased expression of PNPLA2 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 7:141,035,101...141,040,656
Ensembl chr 7:141,035,111...141,040,656
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
affects abundance |
ISO |
PNPLA6 protein affects the abundance of Phosphatidylcholines |
CTD |
PMID:36336212 |
|
NCBI chr 8:3,565,341...3,594,267
Ensembl chr 8:3,565,384...3,594,267
|
|
G |
Pon2 |
paraoxonase 2 |
increases activity increases expression |
EXP |
Phosphatidylcholines results in increased activity of PON2 protein Phosphatidylcholines results in increased expression of PON2 mRNA |
CTD |
PMID:12615656 |
|
NCBI chr 6:5,264,620...5,298,408
Ensembl chr 6:5,264,147...5,298,455
|
|
G |
Pon3 |
paraoxonase 3 |
multiple interactions |
EXP |
Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin] |
CTD |
PMID:12615656 |
|
NCBI chr 6:5,216,253...5,256,236
Ensembl chr 6:5,220,852...5,256,286
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
increases expression |
EXP |
Phosphatidylcholines results in increased expression of PPARG mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1b |
peroxisome proliferative activated receptor, gamma, coactivator 1 beta |
increases abundance |
EXP |
PPARGC1B results in increased abundance of Phosphatidylcholines |
CTD |
PMID:17932310 |
|
NCBI chr18:61,424,516...61,533,846
Ensembl chr18:61,431,207...61,533,502
|
|
G |
Pten |
phosphatase and tensin homolog |
affects binding multiple interactions |
ISO |
PTEN protein binds to Phosphatidylcholines [TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines] |
CTD |
PMID:15313215 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Retn |
resistin |
decreases expression |
EXP |
Phosphatidylcholines results in decreased expression of RETN mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 8:3,705,770...3,709,818
Ensembl chr 8:3,705,770...3,710,110
|
|
G |
Sftpa1 |
surfactant associated protein A1 |
multiple interactions |
ISO |
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]] |
CTD |
PMID:15065867 |
|
NCBI chr14:40,853,745...40,858,330
Ensembl chr14:40,853,739...40,858,409
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
multiple interactions |
ISO |
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases abundance |
ISO EXP |
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] Phosphatidylcholines results in increased expression of TNF mRNA [LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Phosphatidylcholines results in increased expression of and results in increased secretion of TNF protein |
CTD |
PMID:16141546 PMID:22433871 PMID:23911798 PMID:30958839 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein] |
CTD |
PMID:21695227 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines] |
CTD |
PMID:15313215 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
increases expression multiple interactions |
EXP ISO |
Pyocyanine results in increased expression of AHR mRNA Pyocyanine promotes the reaction [AHR protein binds to TARDBP promoter] |
CTD |
PMID:28476168 PMID:31078726 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions increases phosphorylation |
ISO |
Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24015256 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Atf6 |
activating transcription factor 6 |
increases activity |
ISO |
Pyocyanine results in increased activity of ATF6 protein |
CTD |
PMID:27613716 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
EXP |
Pyocyanine results in decreased expression of CCL5 mRNA; Pyocyanine results in decreased expression of CCL5 protein |
CTD |
PMID:31078726 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression |
EXP |
Pyocyanine results in increased expression of CTNNB1 mRNA |
CTD |
PMID:31078726 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
Pyocyanine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:31078726 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Egfr |
epidermal growth factor receptor |
increases phosphorylation |
ISO |
Pyocyanine results in increased phosphorylation of EGFR protein |
CTD |
PMID:24015256 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
decreases expression |
EXP |
Pyocyanine results in decreased expression of FABP4 mRNA |
CTD |
PMID:31078726 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Pyocyanine results in increased expression of GCLC mRNA [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA] |
CTD |
PMID:24015256 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Hsf1 |
heat shock factor 1 |
increases activity |
ISO |
Pyocyanine results in increased activity of HSF1 protein |
CTD |
PMID:27613716 |
|
NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113
|
|
G |
Il10 |
interleukin 10 |
increases expression |
EXP |
Pyocyanine results in increased expression of IL10 protein |
CTD |
PMID:31078726 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il13 |
interleukin 13 |
decreases expression |
EXP |
Pyocyanine results in decreased expression of IL13 protein |
CTD |
PMID:31078726 |
|
NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529
|
|
G |
Il6 |
interleukin 6 |
increases expression |
EXP |
Pyocyanine results in increased expression of IL6 protein |
CTD |
PMID:31078726 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Map2k1 |
mitogen-activated protein kinase kinase 1 |
increases phosphorylation |
ISO |
Pyocyanine results in increased phosphorylation of MAP2K1 protein |
CTD |
PMID:24015256 |
|
NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913
|
|
G |
Map2k2 |
mitogen-activated protein kinase kinase 2 |
increases phosphorylation |
ISO |
Pyocyanine results in increased phosphorylation of MAP2K2 protein |
CTD |
PMID:24015256 |
|
NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24015256 PMID:24316274 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Pyocyanine results in increased phosphorylation of MAPK3 protein Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24015256 PMID:24316274 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions increases activity |
ISO EXP |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with RTKI cpd] inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein; RTKI cpd inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein] Pyocyanine results in increased activity of NFE2L2 protein |
CTD |
PMID:24015256 PMID:27613716 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
increases expression multiple interactions |
ISO |
Pyocyanine results in increased expression of NQO1 mRNA [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA] |
CTD |
PMID:24015256 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
decreases expression |
EXP |
Pyocyanine results in decreased expression of PPARG mRNA |
CTD |
PMID:31078726 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions |
ISO |
Pyocyanine promotes the reaction [AHR protein binds to TARDBP promoter] |
CTD |
PMID:28476168 |
|
NCBI chr 4:148,696,839...148,711,672
Ensembl chr 4:148,696,839...148,711,476
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
Pyocyanine results in increased expression of TNF mRNA |
CTD |
PMID:31078726 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Adgre4 |
adhesion G protein-coupled receptor E4 |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of ADGRE4 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr17:56,056,984...56,160,662
Ensembl chr17:56,056,984...56,160,662
|
|
G |
Adgre5 |
adhesion G protein-coupled receptor E5 |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of ADGRE5 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 8:84,449,874...84,467,812
Ensembl chr 8:84,449,880...84,467,955
|
|
G |
Afp |
alpha fetoprotein |
multiple interactions decreases expression |
EXP |
S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of AFP mRNA] S-Adenosylmethionine results in decreased expression of AFP mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions decreases abundance |
EXP |
PEMT protein promotes the reaction [AHR protein results in decreased abundance of S-Adenosylmethionine] |
CTD |
PMID:29416063 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Alad |
aminolevulinate, delta-, dehydratase |
increases activity |
EXP |
S-Adenosylmethionine results in increased activity of ALAD protein |
CTD |
PMID:9559101 |
|
NCBI chr 4:62,422,762...62,438,300
Ensembl chr 4:62,427,406...62,438,155
|
|
G |
Alas2 |
aminolevulinic acid synthase 2, erythroid |
multiple interactions |
ISO |
[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA] |
CTD |
PMID:24141029 |
|
NCBI chr X:149,330,443...149,353,614
Ensembl chr X:149,330,371...149,353,634
|
|
G |
App |
amyloid beta precursor protein |
increases secretion |
ISO |
S-Adenosylmethionine results in increased secretion of APP protein modified form |
CTD |
PMID:22906069 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
As3mt |
arsenite methyltransferase |
multiple interactions affects binding |
ISO |
Cysteine promotes the reaction [AS3MT protein binds to S-Adenosylmethionine]; Glutathione promotes the reaction [AS3MT protein binds to S-Adenosylmethionine]; S-Adenosylmethionine promotes the reaction [AS3MT protein binds to and results in increased methylation of arsenite]; tris(2-carboxyethyl)phosphine promotes the reaction [AS3MT protein binds to S-Adenosylmethionine] |
CTD |
PMID:22955273 PMID:24124590 PMID:25349987 |
|
NCBI chr19:46,695,124...46,729,538
Ensembl chr19:46,695,897...46,729,538
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
EXP |
S-Adenosylmethionine results in increased expression of ATF3 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atp7b |
ATPase, copper transporting, beta polypeptide |
multiple interactions |
EXP |
ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine] |
CTD |
PMID:22945834 |
|
NCBI chr 8:22,482,799...22,550,347
Ensembl chr 8:22,482,801...22,550,321
|
|
G |
Bhmt2 |
betaine-homocysteine methyltransferase 2 |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [BHMT2 protein results in increased metabolism of Vitamin U] |
CTD |
PMID:18230605 |
|
NCBI chr13:93,792,605...93,810,810
Ensembl chr13:93,792,228...93,810,810
|
|
G |
Casp12 |
caspase 12 |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of CASP12 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases activity |
ISO |
S-Adenosylmethionine inhibits the reaction [Ethanol results in increased activity of CASP3 protein] S-Adenosylmethionine results in decreased activity of CASP3 protein |
CTD |
PMID:17869084 PMID:18571630 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
S-Adenosylmethionine inhibits the reaction [Acetaminophen results in decreased activity of CAT protein] |
CTD |
PMID:22683606 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [sodium arsenite results in decreased expression of CCN1 protein]; S-Adenosylmethionine inhibits the reaction [sodium arsenite results in decreased stability of CCN1 mRNA] |
CTD |
PMID:37682722 |
|
NCBI chr 3:145,352,726...145,355,740
Ensembl chr 3:145,352,731...145,355,736
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [sodium arsenite results in decreased expression of CDH2 protein] |
CTD |
PMID:37682722 |
|
NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
decreases expression multiple interactions |
ISO |
S-Adenosylmethionine results in decreased expression of COL1A1 mRNA S-Adenosylmethionine inhibits the reaction [LEP protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:15983038 PMID:16996477 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Col1a2 |
collagen, type I, alpha 2 |
multiple interactions decreases expression |
EXP ISO |
S-Adenosylmethionine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A2 mRNA]; S-Adenosylmethionine inhibits the reaction [SP1 protein binds to COL1A2 promoter]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein binds to COL1A2 promoter] S-Adenosylmethionine results in decreased expression of COL1A2 mRNA |
CTD |
PMID:8878782 PMID:15983038 |
|
NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[tolcapone results in decreased activity of COMT protein] inhibits the reaction [Levodopa results in increased abundance of S-Adenosylmethionine] |
CTD |
PMID:16758261 |
|
NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
S-Adenosylmethionine inhibits the reaction [Acetaminophen affects the localization of CYCS protein] |
CTD |
PMID:22683606 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
ISO EXP |
S-Adenosylmethionine results in decreased activity of CYP2E1 protein S-Adenosylmethionine inhibits the reaction [CYP2E1 protein results in increased metabolism of 4-nitrophenol]; S-Adenosylmethionine inhibits the reaction [CYP2E1 protein results in increased metabolism of Dimethylnitrosamine]; S-Adenosylmethionine inhibits the reaction [CYP2E1 protein results in increased metabolism of Ethanol] S-Adenosylmethionine inhibits the reaction [Acetaminophen results in decreased expression of CYP2E1 protein]; S-Adenosylmethionine promotes the reaction [Carbon Tetrachloride results in decreased expression of and results in decreased activity of CYP2E1 protein] |
CTD |
PMID:15763544 PMID:15983038 PMID:22683606 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
ISO |
[Levodopa co-treated with DDC] results in increased abundance of S-Adenosylmethionine |
CTD |
PMID:11445284 |
|
NCBI chr11:11,764,101...11,848,144
Ensembl chr11:11,764,101...11,848,144
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [Particulate Matter results in decreased expression of DLG4 protein] |
CTD |
PMID:27624276 |
|
NCBI chr11:69,908,029...69,938,107
Ensembl chr11:69,907,768...69,938,348
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [arsenic trioxide inhibits the reaction [DNMT1 protein binds to ESR1 promoter]]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in decreased expression of DNMT1 protein] |
CTD |
PMID:22558281 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3a |
DNA methyltransferase 3A |
multiple interactions |
ISO EXP |
S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in decreased expression of DNMT3A protein] S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of DNMT3A mRNA] |
CTD |
PMID:18098314 PMID:22558281 |
|
NCBI chr12:3,851,559...3,964,442
Ensembl chr12:3,856,007...3,964,443
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[S-Adenosylmethionine co-treated with Arsenic] affects the expression of EGR1 mRNA; [S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of EGR1 promoter]] which results in decreased expression of EGR1 mRNA; S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of EGR1 promoter] |
CTD |
PMID:35490796 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [[arsenic trioxide results in increased expression of ESR1 protein] which results in increased expression of GREB1 mRNA]; S-Adenosylmethionine inhibits the reaction [[arsenic trioxide results in increased expression of ESR1 protein] which results in increased expression of TFF1 mRNA]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide inhibits the reaction [DNMT1 protein binds to ESR1 promoter]]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in decreased methylation of ESR1 promoter]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of ESR1 mRNA]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of ESR1 protein] |
CTD |
PMID:22558281 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Fcgr1 |
Fc receptor, IgG, high affinity I |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of FCGR1 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 3:96,190,225...96,201,285
Ensembl chr 3:96,190,225...96,201,285
|
|
G |
Fgf15 |
fibroblast growth factor 15 |
increases abundance |
EXP |
FGF19 protein results in increased abundance of S-Adenosylmethionine |
CTD |
PMID:29416063 |
|
NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690
|
|
G |
Fgl2 |
fibrinogen-like protein 2 |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of FGL2 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 5:21,577,671...21,583,384
Ensembl chr 5:21,577,640...21,583,372
|
|
G |
Gbp2 |
guanylate binding protein 2 |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of GBP2 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 3:142,326,424...142,343,769
Ensembl chr 3:142,326,363...142,343,769
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]] |
CTD |
PMID:20146260 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
decreases abundance |
EXP |
GCLM protein mutant form results in decreased abundance of S-Adenosylmethionine |
CTD |
PMID:38830566 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Greb1 |
gene regulated by estrogen in breast cancer protein |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [[Arsenic Trioxide results in increased expression of ESR1 protein] which results in increased expression of GREB1 mRNA]; S-Adenosylmethionine inhibits the reaction [Arsenic Trioxide results in increased expression of GREB1 mRNA] |
CTD |
PMID:22558281 |
|
NCBI chr12:16,720,616...16,851,395
Ensembl chr12:16,720,616...16,850,887
|
|
G |
Gsr |
glutathione reductase |
multiple interactions |
EXP |
S-Adenosylmethionine inhibits the reaction [Acetaminophen results in decreased activity of GSR protein] |
CTD |
PMID:22683606 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gss |
glutathione synthetase |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]] |
CTD |
PMID:20146260 |
|
NCBI chr 2:155,405,101...155,434,730
Ensembl chr 2:155,405,101...155,434,730
|
|
G |
Gstm2 |
glutathione S-transferase, mu 2 |
multiple interactions |
EXP |
S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of GSTM2 mRNA] |
CTD |
PMID:18098314 |
|
NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769
|
|
G |
H2-Eb1 |
histocompatibility 2, class II antigen E beta |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of H2-EB1 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr17:34,524,841...34,535,648
Ensembl chr17:34,524,841...34,535,648
|
|
G |
Hand2 |
heart and neural crest derivatives expressed 2 |
multiple interactions |
EXP |
[Progesterone co-treated with S-Adenosylmethionine] results in increased methylation of HAND2 promoter; S-Adenosylmethionine inhibits the reaction [Progesterone results in increased expression of HAND2 mRNA] |
CTD |
PMID:30892605 |
|
NCBI chr 8:57,774,018...57,777,552
Ensembl chr 8:57,774,018...57,777,668
|
|
G |
Hbb-b1 |
hemoglobin, beta adult major chain |
multiple interactions |
ISO |
[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA] |
CTD |
PMID:24141029 |
|
|
|
G |
Hdac9 |
histone deacetylase 9 |
multiple interactions |
EXP |
S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of HDAC9 mRNA] |
CTD |
PMID:18098314 |
|
NCBI chr12:34,097,579...34,967,094
Ensembl chr12:34,097,579...34,967,094
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
multiple interactions |
ISO |
[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA] |
CTD |
PMID:24141029 |
|
NCBI chr 9:44,247,645...44,255,525
Ensembl chr 9:44,247,636...44,255,525
|
|
G |
Ifi44l |
interferon-induced protein 44 like |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of IFI44L mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 3:151,464,374...151,468,528
Ensembl chr 3:151,464,374...151,468,529
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IFNG mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
S-Adenosylmethionine inhibits the reaction [Thioacetamide results in increased expression of IL1B protein] S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IL1B mRNA] |
CTD |
PMID:17080400 PMID:19822164 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IL2 mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il2rg |
interleukin 2 receptor, gamma chain |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of IL2RG mRNA |
CTD |
PMID:18098314 |
|
NCBI chr X:100,307,991...100,311,861
Ensembl chr X:100,307,984...100,311,861
|
|
G |
Il36g |
interleukin 36G |
decreases expression |
EXP |
S-Adenosylmethionine results in decreased expression of IL36G mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 2:24,076,488...24,083,579
Ensembl chr 2:24,076,488...24,083,580
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
S-Adenosylmethionine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IL6 mRNA] |
CTD |
PMID:17080400 PMID:19822164 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Klf6 |
Kruppel-like transcription factor 6 |
decreases expression multiple interactions |
EXP |
S-Adenosylmethionine results in decreased expression of KLF6 mRNA S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of KLF6 mRNA] |
CTD |
PMID:18098314 |
|
NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [LEP protein results in increased expression of COL1A1 mRNA]; S-Adenosylmethionine inhibits the reaction [Vitamin K 3 results in increased expression of LEP mRNA] |
CTD |
PMID:16996477 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Ltb |
lymphotoxin B |
multiple interactions |
EXP |
S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of LTB mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr17:35,413,483...35,415,281
Ensembl chr17:35,413,415...35,415,296
|
|
G |
Maf |
MAF bZIP transcription factor |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein]] |
CTD |
PMID:20146260 |
|
NCBI chr 8:116,429,992...116,433,633
Ensembl chr 8:116,409,681...116,434,533
|
|
G |
Mafg |
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) |
multiple interactions |
ISO |
S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein]] |
CTD |
PMID:20146260 |
|
NCBI chr11:120,515,943...120,525,771
Ensembl chr11:120,515,943...120,524,426
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP ISO |
S-Adenosylmethionine inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK1 protein] [1,2-linoleoylphosphatidylcholine co-treated with S-Adenosylmethionine] inhibits the reaction [Vitamin K 3 results in increased phosphorylation of MAPK1 protein]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK1 protein modified form]] |
CTD |
PMID:15983038 PMID:16996477 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP ISO |
S-Adenosylmethionine inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK3 protein] [1,2-linoleoylphosphatidylcholine co-treated with S-Adenosylmethionine] inhibits the reaction [Vitamin K 3 results in increased phosphorylation of MAPK3 protein]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK3 protein modified form]] |
CTD |
PMID:15983038 PMID:16996477 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mat1a |
methionine adenosyltransferase 1A |
affects abundance increases chemical synthesis |
EXP |
MAT1A affects the abundance of S-Adenosylmethionine MAT1A protein results in increased chemical synthesis of S-Adenosylmethionine |
CTD |
PMID:8373829 PMID:12060674 |
|
NCBI chr14:40,826,969...40,846,385
Ensembl chr14:40,826,992...40,846,369
|
![JBrowse link JBrowse link]() | |